Login to Your Account



Actelion Pays for Option to Buy Trophos for up to $251M

By Nuala Moran


Wednesday, July 21, 2010
LONDON – Actelion Pharmaceuticals Ltd. is paying €10 million (US$12.9 million) in cash for the option to acquire Trophos SA for up to €195 million cash once it gets Phase III data on olesoxime, a treatment for amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription